<DOC>
	<DOCNO>NCT00003798</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs gadolinium texaphyrin may make tumor cell sensitive radiation therapy . PURPOSE : Phase I trial study effectiveness gadolinium texaphyrin plus radiation therapy treat patient cancer pancreas remove surgery .</brief_summary>
	<brief_title>Radiation Therapy Plus Gadolinium Texaphyrin Treating Patients With Cancer Pancreas That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose gadolinium texaphyrin patient locally advance , unresectable pancreatic periampullary adenocarcinoma undergo local regional radiotherapy . II . Determine toxic effect gadolinium texaphyrin concurrent radiotherapy patient . III . Correlate estimate tumor normal organ gadolinium texaphyrin uptake retention time MRI plasma/serum level patient . OUTLINE : This dose escalation study . Patients receive gadolinium texaphyrin IV 5-10 minute 4 time weekly least 2 hour prior external beam radiotherapy 2.5 week ( total 10 fraction ) . Cohorts 3-6 patient treat escalate dos gadolinium texaphyrin . The maximum tolerate dose defined high dose level dose limit toxicity occur 2 6 patient . Patients follow monthly 2 month . PROJECTED ACCRUAL : A total 45 evaluable patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locally advanced , unresectable pancreatic periampullary adenocarcinoma Patients may evidence hepatic intraabdominal systemic metastasis dominant symptomatology locally unresectable component disease Prior treatment 1 chemotherapy regimen require Palliative bypass procedure without resection allow Bidimensionally measurable disease CT MRI scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 150,000/mm3 Hemoglobin least 8.5 g/dL No history G6PD deficiency Hepatic : SGOT SGPT less 2 time upper limit normal ( ULN ) Alkaline phosphatase less 2 time ULN Bilirubin great 2.0 mg/dL ( elevated value must fall stable least 1 week prior therapy ) Renal : Creatinine great 2.0 mg/dL ( clinical indication compromise kidney ) Other : Not pregnant nursing Fertile patient must use effective contraception No second malignancy within past 5 year , except : Resected superficial nonmelanomatous skin cancer Carcinoma situ cervix No uncontrolled serious medical condition No active peptic ulcer No weight loss great 5 % ideal body weight within 30 day prior study No uncontrolled nausea vomit No claustrophobia PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy No concurrent experimental biologic therapy Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy compromise delivery radiation study No prior radiotherapy area within planned field treatment Surgery : At least 4 week since prior gastrointestinal surgery Other : At least 4 week since prior experimental drug No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>